To Be Discontinued Capsule Endocrinology/Metabolism
Paricalcitol Capsule · 339 days since initial FDA posting
Brand: ZEMPLAR
FDA lists Paricalcitol Capsule as To Be Discontinued (AbbVie Inc.).
No availability text on this FDA row.
Paricalcitol Capsule: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Paricalcitol Capsule
- Manufacturer
- AbbVie Inc.
- Dosage Form
- Capsule
- Presentation
- Zemplar, Capsule, 2 ug (NDC 0074-9037-30)
- Package NDC
- 0074-9037-30
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 7, 2025
- Last Updated
- Oct 7, 2025
- Therapeutic Category
- Endocrinology/Metabolism
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Paricalcitol Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.